T3D Therapeutics
Hoda Gabriel, a highly experienced professional in the pharmaceutical industry, currently holds the position of Vice President, Clinical Development at T3D Therapeutics, Inc. With a background in Chemistry from North Carolina State University, Hoda has held various key roles in companies such as Oculus Research, GlaxoSmithKline Pharma GmbH, Talecris Biotherapeutics, Inc., and Carolina Advanced Research. As a founder and board member at Oculus Research, Hoda has made significant contributions to the field of pharmaceuticals.
This person is not in any offices
T3D Therapeutics
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.